journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lung Cancer

journal
https://www.readbyqxmd.com/read/28318951/a-comprehensive-analysis-of-programmed-cell-death-ligand-1-expression-with-the-clone-sp142-antibody-in-non-small-cell-lung-cancer%C3%A2-patients
#1
Kazuki Takada, Gouji Toyokawa, Tatsuro Okamoto, Mototsugu Shimokawa, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Fumihiro Shoji, Yoshinao Oda, Yoshihiko Maehara
BACKGROUND: Programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have been identified as novel targets for immunotherapy, with anti-PD-1 therapy currently the standard treatment for non-small-cell lung cancer (NSCLC) patients after the failure of first-line chemotherapy treatment. The recent phase II POPLAR and phase III OAK studies showed that atezolizumab, a representative PD-L1 inhibitor, exhibited a survival benefit compared with standard therapy in patients with NSCLC...
March 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28302437/definitive-radiotherapy-for-local-recurrence-of-nsclc-after-surgery
#2
Abraham J Wu, Elizabeth Garay, Amanda Foster, Meier Hsu, Zhigang Zhang, Jamie E Chaft, James Huang, Kenneth E Rosenzweig, Andreas Rimner
INTRODUCTION: Locoregional recurrence after resection of non-small-cell lung cancer (NSCLC) is common. We examined outcomes after definitive radiotherapy (RT) to identify prognostic factors for survival and further recurrence. PATIENTS AND METHODS: We reviewed 152 patients who received RT for locoregional recurrent (LR)-NSCLC, and analyzed subsequent overall survival (OS), locoregional failure (LRF), distant metastasis (DM), and any disease progression (LRF and DM)...
February 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28245967/pulsatile-erlotinib-in-egfr-positive-non-small-cell-lung-cancer-patients-with-leptomeningeal-and-brain-metastases-review%C3%A2-of%C3%A2-the-literature
#3
REVIEW
Joan How, Janelle Mann, Andrew N Laczniak, Maria Q Baggstrom
Patients with epidermal growth factor receptor (EGFR)-positive (EGFR(+)) non-small-cell lung cancer (NSCLC) show improved response rates when treated with tyrosine kinase inhibitors (TKIs) such as erlotinib. However, standard daily dosing of erlotinib often does not reach therapeutic concentrations within the cerebrospinal fluid (CSF), resulting in progression of central nervous system (CNS) disease. Intermittent, high-dose administration of erlotinib reaches therapeutic concentrations within the CSF and is well tolerated in patients...
February 9, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28274690/the-controlling-nutritional-status-score-is-a-significant-independent-predictor-of-poor-prognosis-in-patients-with-malignant-pleural-mesothelioma
#4
Shinkichi Takamori, Gouji Toyokawa, Kenichi Taguchi, Makoto Edagawa, Shinichiro Shimamatsu, Ryo Toyozawa, Kaname Nosaki, Takashi Seto, Fumihiko Hirai, Masafumi Yamaguchi, Fumihiro Shoji, Tatsuro Okamoto, Mitsuhiro Takenoyama, Yukito Ichinose
INTRODUCTION: Malignant pleural mesothelioma (MPM) is a devastating neoplasm; however, some patients exhibit a good response to chemotherapy or multidisciplinary therapy, including surgery and chemotherapy. It is therefore important to discover the factors that can be used to select patients who will benefit from such treatment. Although the Controlling Nutritional Status (CONUT) score has been used to predict the prognosis in other types of malignancy, its utility in patients with MPM is unknown...
February 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28237243/non-small-cell-lung-cancer-patients-with-adenocarcinoma-morphology-have-a-better-outcome-compared-with-patients-diagnosed-with-non-small-cell-lung-cancer-favor-adenocarcinoma
#5
Iris Shiran, Eyal Heller, Shlomit Jessel, Iris Kamer, Inbal Daniel-Meshulam, Rossie Navon, Damien Urban, Amir Onn, Jair Bar
BACKGROUND: Non-small-cell lung cancer (NSCLC) includes 2 major histologic subtypes: squamous cell carcinoma and non-squamous carcinoma, mainly adenocarcinoma, a distinction that carries significant clinical and therapeutic implications. NSCLC is diagnosed as adenocarcinoma or as squamous cell carcinoma on the basis of histologic parameters. However, when morphology is inconclusive, tumors with immunohistochemistry (IHC) findings characteristic of adenocarcinoma are referred to as "NSCLC favor adenocarcinoma" (NFA)...
February 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28237242/early-results-of-lung-cancer-screening-and-radiation-dose-assessment-by-low-dose-ct-at-a-community-hospital
#6
Corbin D Jacobs, Mary Ellen Jafari
BACKGROUND: The National Lung Screening Trial showed a reduction in overall and cancer-specific mortality for patients screened with low-dose computed tomography (LDCT) versus chest radiograph. Some question whether this can be achieved in community healthcare settings. Our aim was to analyze lung cancer screening outcomes and administered radiation dose using LDCT scans at a community hospital. PATIENTS AND METHODS: We retrospectively reviewed the records of 680 patients who underwent LDCT between June 2014 and December 2015, and who met Centers for Medicare and Medicaid Services lung cancer screening criteria: asymptomatic, aged 55 to 77 years, smoked within the last 15 years, and ≥ 30 pack-year history...
February 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28233696/a-multimedia-self-management-intervention-to-prepare-cancer-patients-and-family-caregivers-for-lung-surgery-and-postoperative-recovery
#7
Virginia Sun, Dan J Raz, Nora Ruel, Walter Chang, Loretta Erhunmwunsee, Karen Reckamp, Brian Tiep, Betty Ferrell, Ruth McCorkle, Jae Y Kim
BACKGROUND: The purpose of this study was to evaluate the feasibility and acceptability of a multimedia self-management (MSM) intervention to prepare patients and family caregivers for lung surgery. PATIENTS AND METHODS: This is a quasi-experimental, 2-group, sequential enrollment pilot study of a 4-session multimedia intervention (audio/visual + print) to enhance self-management and quality of life (QOL) for patients and family caregivers. The intervention, Preparing for Lung Surgery, begins before surgery, and continues through hospitalization and discharge, with 2 telephone support sessions after discharge...
February 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28215851/a-novel-neoadjuvant-therapy-for-operable-locally-invasive-non-small-cell-lung-cancer-phase-i-study-of-neoadjuvant-stereotactic-body-radiotherapy-linnearre-i-nct02433574
#8
Nhu-Tram A Nguyen, Naghmeh Isfahanian, Gregory Pond, Wael Hanna, Jean-Claude Cutz, James Wright, Anand Swaminath, Yaron Shargall, Tom Chow, Marcin Wierzbicki, Gordon Okawara, Kimmen Quan, Christian Finley, Rosalyn Juergens, Theodoros Tsakiridis
BACKGROUND: Despite improved staging and surgical techniques, the rate of incomplete resection (R1) of non-small-cell lung cancer (NSCLC) has not significantly decreased. Patients with R1 resection have worse survival compared with those with complete resection (R0). Stereotactic body radiotherapy (SBRT) is a rapid and convenient radiotherapy treatment that delivers high-dose radiotherapy to tumors with high precision while sparing normal organs. Although its efficacy in treating small lung tumors is documented, its use as neoadjuvant therapy for locally advanced (LA) NSCLC has not been examined...
January 31, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28189594/addressing-the-palliative-setting-in-advanced-lung-cancer-should-not-remain-a-barrier-a%C3%A2-multicenter-study
#9
Annelies Janssens, Sofie Derijcke, Anneke Lefebure, Elke Vandenbroucke, Veerle Surmont, Dieter Coeman, Daniëlle Galdermans, Ann-Marie Morel, Birgitta I Hiddinga, Jan P van Meerbeeck
BACKGROUND: Implementation of early palliative care (EPC) into daily oncology practice remains difficult. One of the barriers preventing oncologists from starting EPC is open communication about the palliative setting. The aim of this study was to investigate the relevance of this communication barrier. PATIENTS AND METHODS: In this cross-sectional multicenter study, 106 patients with advanced thoracic cancer were issued a questionnaire to survey 3 dimensions of interest: illness understanding, observation of conversation regarding prognosis and end-of-life (EoL) care, and information preferences of the patients...
January 20, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28189593/external-validation-of-a-prognostic-score-for-patients-receiving-palliative-thoracic-radiotherapy-for-lung-cancer
#10
Carsten Nieder, Terje Tollåli, Ellinor Haukland, Anne Reigstad, Liv Randi Flatøy, Astrid Dalhaug
BACKGROUND: Palliative thoracic radiotherapy is a common treatment for patients with incurable lung cancer. A recent study suggested that a prognostic score based on performance status and N and M stage predicts survival and might support decision-making (eg, when deciding about fractionation). Our aim was to perform a validation study in an independent, larger dataset. PATIENTS AND METHODS: This was a retrospective single-institution study of 232 patients with small- or non-small-cell lung cancer, with methodology comparable with that of the original study...
January 19, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28185793/establishment-of-an-adjusted-prognosis-analysis-model-for-initially-diagnosed-non-small-cell-lung-cancer-with-brain-metastases-from-sun-yat-sen-university-cancer-center
#11
Xiao-Xiao Dinglin, Shu-Xiang Ma, Fang Wang, De-Lan Li, Jian-Zhong Liang, Xin-Ru Chen, Qing Liu, Yin-Duo Zeng, Li-Kun Chen
BACKGROUND: The current published prognosis models for brain metastases (BMs) from cancer have not addressed the issue of either newly diagnosed non-small-cell lung cancer (NSCLC) with BMs or the lung cancer genotype. We sought to build an adjusted prognosis analysis (APA) model, a new prognosis model specifically for NSCLC patients with BMs at the initial diagnosis using adjusted prognosis analysis (APA). PATIENTS AND METHODS: The model was derived using data from 1158 consecutive patients, with 837 in the derivation cohort and 321 in the validation cohort...
January 13, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28188101/antiangiogenic-therapy-in-advanced-non-small-cell-lung-cancer-a-meta-analysis-of-phase-iii-randomized-trials
#12
REVIEW
Jacques Raphael, Kelvin Chan, Safiya Karim, Robert Kerbel, Henry Lam, Keemo Delos Santos, Ronak Saluja, Sunil Verma
We conducted a meta-analysis to evaluate the efficacy of adding any antiangiogenic therapy (AT) to the standard of care in advanced non-small-cell lung cancer (NSCLC). The electronic databases Ovid PubMed, Cochrane Central Register of Controlled Trials, and Embase were searched to identify eligible trials. We included all phase III randomized trials with any line and type of treatment, histology. and AT dose. Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and pooled odds ratio (OR) for overall response rates (RR) were calculated...
January 12, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28185792/randomized-phase-iii-study-of-docetaxel-plus-cisplatin-versus-pemetrexed-plus-cisplatin-as-first-line-treatment-of-nonsquamous-non-small-cell-lung-cancer-a-trail-trial
#13
Cheol-Kyu Park, In-Jae Oh, Kyu-Sik Kim, Yoo-Duk Choi, Tae-Won Jang, Youn-Seup Kim, Kwan-Ho Lee, Kyeong-Cheol Shin, Chi Young Jung, Sei-Hoon Yang, Jeong-Seon Ryu, Seung-Hun Jang, Seung-Soo Yoo, Suk-Joong Yong, Kye Young Lee, Kwang-Ho In, Min-Ki Lee, Young-Chul Kim
INTRODUCTION: To date, no prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in patients with nonsquamous non-small-cell lung cancer. MATERIALS AND METHODS: A total of 148 chemotherapy-naive patients lacking driver mutations were randomized into 21-day regimens of cisplatin 70 mg/m(2) with either docetaxel 60 mg/m(2) (n = 71) or pemetrexed 500 mg/m(2) (n = 77) for ≤ 4 cycles...
January 11, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28162944/epidermal-growth-factor-receptor-egfr-mutation-in-exon-19-p-e749q-confers-resistance-to-gefitinib-in-one-patient-with-lung-adenocarcinoma
#14
Giovenzio Genestreti, Dario de Biase, Monica Di Battista, Giovanna Cavallo, Roberta Degli Esposti, Michela Visani, Giorgia Acquaviva, Thomas Brand, Annalisa Pession, Giovanni Tallini, Alba A Brandes
No abstract text is available yet for this article.
January 11, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28188100/the-use-of-antiangiogenic-agents-for-lung-cancer-in-elderly-patients-an-expert-panel-discussion-synopsis
#15
Mark A Socinski, Jamie E Chaft, Benjamin Levy, Gregory J Riely, Corey J Langer, Roman Perez-Soler, Deborah L Middleton, Linda Gracie-King, Laura M Healy
No abstract text is available yet for this article.
January 5, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28185791/evolution-of-symptom-burden-of-advanced-lung-cancer-over-a-decade
#16
Mike R Sung, Milan V Patel, Sarvar Djalalov, Lisa W Le, Frances A Shepherd, Ronald L Burkes, Ronald Feld, Stephanie Lin, Roxana Tudor, Natasha B Leighl
INTRODUCTION: Lung cancer is associated with higher levels of symptom distress and unmet needs than other cancer types. We assessed changes in symptoms, function, understanding, and preferences of patients with advanced lung cancer over a 10-year period. MATERIALS AND METHODS: A 26-item self-administered questionnaire was used to assess symptom burden, functional impairment, knowledge of disease and treatment, and information preferences. The survey was administered to consecutive outpatients with advanced lung cancer first in 2002 and a second cohort in 2012...
January 5, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28162946/first-clinical-report-of-proton-beam-therapy-for-postoperative-radiotherapy-for-non-small-cell-lung-cancer
#17
Jill S Remick, Caitlin Schonewolf, Peter Gabriel, Abigail Doucette, William P Levin, John C Kucharczuk, Sunil Singhal, Taine T V Pechet, Ramesh Rengan, Charles B Simone, Abigail T Berman
BACKGROUND AND PURPOSE: The characteristic Bragg peak of proton beam therapy (PBT) allows for sparing normal tissues beyond the tumor volume that may allow for decreased toxicities associated with postoperative radiation therapy (PORT). Here we report the first institutional experience with proton therapy for PORT in patients with non-small-cell lung cancer (NSCLC) and assess early toxicities and outcomes. MATERIALS AND METHODS: We identified 61 consecutive patients treated from 2011 to 2014 who underwent PORT for locally advanced NSCLC for positive microscopic margins and/or positive N2 lymph nodes (stage III), with 27 patients receiving PBT and 34 receiving intensity-modulated radiation therapy (IMRT)...
January 5, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28131635/effect-of-combined-therapy-inhibiting-egfr-and-vegfr-pathways-in-non-small-cell-lung-cancer-on-progression-free-and-overall-survival
#18
Tao Jiang, Meng Qiao, Fei Zhou, Shengxiang Ren, Chunxia Su, Caicun Zhou
BACKGROUND: To investigate the effect of combined epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) receptor (VEGFR) pathway inhibitors on progression-free survival (PFS) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: We included 15 randomized clinical trials that had compared the combination of EGFR tyrosine kinase inhibitors and anti-VEGF/VEGFR therapy with different control groups...
December 29, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28131636/superior-treatment-response-and-in-field-tumor-control-in-epidermal-growth-factor-receptor-mutant-genotype-of-stage-iii-nonsquamous-non-small-cell-lung-cancer-undergoing-definitive-concurrent-chemoradiotherapy
#19
Yu Jin Lim, Ji Hyun Chang, Hak-Jae Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Jin Chul Paeng, Keon Wook Kang, June-Key Chung, Yoon Kyung Jeon, Doo Hyun Chung, Hong-Gyun Wu
BACKGROUND: Although previous in vitro data have suggested a more radio-sensitive nature of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) cell lines, the clinical behavior according to the EGFR mutational status has not been well-established. In this study, we performed a comparative outcome analysis of EGFR-mutant and wild-type locally advanced NSCLC with chemoradiotherapy (CRT). PATIENTS AND METHODS: A total of 102 patients with stage III nonsquamous NSCLC undergoing primary CRT were identified...
December 28, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28111120/real-world-eq5d-health-utility-scores-for-patients-with-metastatic-lung-cancer-by-molecular-alteration-and-response-to-therapy
#20
Catherine Labbé, Yvonne Leung, João Gabriel Silva Lemes, Erin Stewart, Catherine Brown, Andrea Perez Cosio, Mark Doherty, Grainne M O'Kane, Devalben Patel, Nicholas Cheng, Mindy Liang, Gursharan Gill, Alexandra Rett, Hiten Naik, Lawson Eng, Nicole Mittmann, Natasha B Leighl, Penelope A Bradbury, Frances A Shepherd, Wei Xu, Geoffrey Liu, Doris Howell
INTRODUCTION: Economic analyses of upcoming treatments for lung cancer benefit from real-world health utility scores (HUSs) in an era of targeted therapy. METHODS: A longitudinal cohort study at Princess Margaret Cancer Centre evaluated 1571 EQ5D-3L-derived HUSs in 475 outpatients with metastatic lung cancer across various disease states. Patients with epidermal growth factor receptor (EGFR) (n = 183) and anaplastic lymphoma kinase (ALK) (n = 38) driver alterations were enriched through targeted enrolment; patients with wild-type non-small-cell lung cancer (WT NSCLC) (n = 224) and small-cell lung cancer (SCLC) (n = 30) were sampled randomly...
December 28, 2016: Clinical Lung Cancer
journal
journal
34772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"